TIDMPOLX

RNS Number : 0386A

Polarean Imaging PLC

23 May 2019

Polarean Imaging Plc

("Polarean" or the "Company")

Grant of Share Options

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that upon the recommendation of the Company's Remuneration Committee it has granted options over a total of 1,200,000 ordinary shares of 0.00037p each in the Company ("Ordinary Shares") to Chuck Osborne, Chief Financial Officer (the "Options").

The exercise price for the Options is 15 pence and 25% of the Options shall vest on 29 April 2020, whilst the remaining 75% of the Options shall vest in equal portions on the last day of each calendar month over the period of 36 months, starting on 31 May 2020.

Following the grant of the Options referred to above, there are 22,394,131 outstanding options and warrants over Polarean's Ordinary Shares, representing 18% of the Company's Ordinary Shares and total voting rights on a fully diluted basis.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

 
 Polarean Imaging plc                              www.polarean.com / www.polarean-ir.com 
 Richard Hullihen, Chief Executive Officer                                Via Walbrook PR 
 Richard Morgan, Chairman 
 
 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470 
 David Hignell / Lindsay Mair / Jamie Spotswood 
  (Corporate Finance) 
  Vadim Alexandre / Rob Rees (Corporate Broking) 
 
 Walbrook PR                          Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com 
 Paul McManus / Anna Dunphy                        Mob: +44 (0)7980 541 893 / +44 (0)7879 
                                                                                  741 001

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging (129) Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimise the imaging of (129) Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
  1   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Names                       Charles F Osborne Jr 
     --------------------------  ---------------------------------------- 
 2    Reason for the notification 
     -------------------------------------------------------------------- 
 a)   Position/status             CFO (Non-Board) 
     --------------------------  ---------------------------------------- 
 b)   Initial notification        Initial Notification 
       /Amendment 
     --------------------------  ---------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     -------------------------------------------------------------------- 
 a)   Name                        Polarean Imaging Plc ("Polarean") 
     --------------------------  ---------------------------------------- 
 b)   LEI                         213800DGR2BHXJ36OL37 
     --------------------------  ---------------------------------------- 
 4    Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     -------------------------------------------------------------------- 
 a)   Description of the          Options over Polarean's ordinary shares 
       financial instrument,       of GBP0.0037p each (the "Options") 
       type of instrument 
     --------------------------  ---------------------------------------- 
 b)   Identification code         GB00BF3DT583 
     --------------------------  ---------------------------------------- 
 c)   Nature of the transaction   Grant of Options 
     --------------------------  ---------------------------------------- 
 d)   Price and volumes           Exercise Price - 15p per Option 
                                   Volume of Options: 1,200,000 
     --------------------------  ---------------------------------------- 
 d)   Aggregated information       Volume: 1,200,000 Options 
       - Aggregated volume          Price: Each Option has an exercise 
       - Price                      price of 15p 
     --------------------------  ---------------------------------------- 
 e)   Date of the transaction     23 May 2019 
     --------------------------  ---------------------------------------- 
 f)   Place of the transaction    London Stock Exchange, AIM Market 
     --------------------------  ----------------------------------------

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHSEDFLDFUSEEI

(END) Dow Jones Newswires

May 23, 2019 10:26 ET (14:26 GMT)

Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Polarean Imaging.
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Polarean Imaging.